Login
Companies $PRAX
$310.27 -$17.86 (5.44%) Live
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

praxismedicines.com

What Do They Do?

Develops small-molecule and antisense medicines for people with epilepsy and movement disorders.

Who Are Their Customers?

Praxis works with Tenacia under an exclusive license to develop and commercialize ulixacaltamide in China, Hong Kong, Macau and Taiwan.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −27% (Loss)
vs −$73.9M in Q3 FY2025
  • Jul 7, 2026 Praxis partnered with Remagine Labs to develop a transdermal ulixacaltamide patch The collaboration applies Remagine’s delivery platform to ulixacaltamide and includes an equity investment in Remagine.
  • Jun 29, 2026 Praxis replaced Ernst & Young with KPMG as its independent auditor The company reported no disagreements with its former auditor or reportable events.

Ulixacaltamide advances Ulixacaltamide has moved from clinical testing for essential tremor to an NDA submission and commercial preparations.

Epilepsy pipeline focus The earlier report centered its small-molecule discussion on a candidate for rare epilepsies; the latest describes relutrigine for developmental epilepsies and vormatrigine for common epilepsies.

Who Do They Compete With?

Competes with SK-Pharma, Xenon Pharmaceuticals, Biohaven Pharmaceuticals, Lundbeck, and Stoke Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support